London · Delayed Price · Currency is GBP · Price in GBX CVS Group Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and EBITDA grew despite inflation and weak UK consumer confidence, with strong margin performance in Australia and ongoing disciplined M&A. Most CMA compliance measures are already in place, and further margin improvement is expected as cost pressures ease.
-
Revenue grew 5.8% year-over-year to GBP 356.9 million, with adjusted EBITDA up 3.9% and strong cash flow supporting continued investment. Australia now contributes 10% of revenue and 15% of EBITDA, while the group maintains leverage well below its target ceiling.
Fiscal Year 2025
-
Revenue rose 5.4% to £673.2m and adjusted EBITDA grew 9.4%, with strong cash generation and leverage reduced to 1.18x. Expansion in Australia continues, UK acquisitions are set to resume post-CMA, and medium-term like-for-like growth guidance is 4–8%.
-
Revenue grew 5.4% to £673.2m, with adjusted EBITDA up 9.4% and margin at 20%. Australian expansion continued, and UK operations improved, with strong cash flow and reduced leverage. Confident in medium-term 4%-8% growth, supported by efficiency gains and selective acquisitions.
-
Revenue grew 5.4% to GBP 673.2 million, with Adjusted EBITDA up 9.4% and margin at 20%. Strong cash flow, reduced leverage, and continued expansion in Australia position the group for further growth, despite ongoing CMA investigation and sector headwinds.
-
Revenue rose 6.6% to £341.8m and EBITDA grew 4.5% to £67.4m, with strong expansion in Australia and a robust acquisition pipeline. Despite UK regulatory uncertainty and cost pressures, the business remains confident in its growth targets and margin ambitions.
Fiscal Year 2024
-
Revenue grew 9.9% to £647.3m, with adjusted EBITDA up 4.7% to £127.3m, driven by UK and Australian acquisitions. Despite headwinds from a cyber incident and CMA scrutiny, confidence remains in meeting full-year expectations and margin targets.